Clonal Cytopenia of Undetermined Significance Clinical Trials

10 recruiting

Clonal Cytopenia of Undetermined Significance Trials at a Glance

12 actively recruiting trials for clonal cytopenia of undetermined significance are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in St Louis, Rochester, and New York. Lead sponsors running clonal cytopenia of undetermined significance studies include Mayo Clinic, Washington University School of Medicine, and M.D. Anderson Cancer Center.

Browse clonal cytopenia of undetermined significance trials by phase

Treatments under study

About Clonal Cytopenia of Undetermined Significance Clinical Trials

Looking for clinical trials for Clonal Cytopenia of Undetermined Significance? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Clonal Cytopenia of Undetermined Significance trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Clonal Cytopenia of Undetermined Significance clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Early Phase 1

Early Intervention in High Risk CCUS

Clonal Cytopenia of Undetermined SignificanceCytopenia
Lachelle D. Weeks, MD, PhD108 enrolled1 locationNCT06802146
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting

CHIP/CCUS Natural History Protocol

Clonal Cytopenia of Undetermined SignificanceClonal Hematopoiesis of Indeterminate Potential
National Heart, Lung, and Blood Institute (NHLBI)306 enrolled1 locationNCT04102423
Recruiting
Phase 2

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Myelodysplastic SyndromesClonal Cytopenia of Undetermined Significance
Washington University School of Medicine16 enrolled1 locationNCT05483010
Recruiting
Phase 2

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Myelodysplastic SyndromeMyelofibrosisPolycythemia Vera+2 more
University of Southern California30 enrolled2 locationsNCT06063486
Recruiting
Phase 2

Luspatercept for Clonal Cytopenias of Uncertain Significance

ThrombocytopeniaNeutropeniaAnemia+2 more
Weill Medical College of Cornell University50 enrolled1 locationNCT06788691
Recruiting

CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research

Clonal HematopoiesisHematologic Disease and DisordersCCUS Clonal Cytopenia of Undetermined Significance
Clinical Hub for Interventional Research (CHOIR)100 enrolled1 locationNCT07313059
Recruiting
Phase 2

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center15 enrolled1 locationNCT06566742
Recruiting
Not Applicable

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Hematopoietic and Lymphatic System NeoplasmHematologic NeoplasmsMyeloid Malignancy+10 more
Mayo Clinic2,000 enrolled3 locationsNCT02958462
Recruiting
Phase 2

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined Significance
Washington University School of Medicine15 enrolled1 locationNCT06240754
Recruiting
Phase 2

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Clonal Cytopenia of Undetermined Significance
Uma Borate110 enrolled6 locationsNCT05641831